Thus, CU-ACC2 cells, which express neither the MDR1 drug efflux transporter nor SLFN11, show a marked decrease in DNA replication and G2–M-phase arrest after TAK-243 treatment, while being the most sensitive ACC cell line to TAK-243. Here, SLFN11 is linked to adrenal cortex carcinoma.